...
首页> 外文期刊>Acta orthopaedica. >Celecoxib does not appear to affect prosthesis fixation in total knee replacement
【24h】

Celecoxib does not appear to affect prosthesis fixation in total knee replacement

机译:塞来昔布似乎不影响全膝关节置换术中的假体固定

获取原文
           

摘要

Background and purpose After joint replacement, a repair process starts at the interface between bone and cement. If this process is disturbed, the prosthesis may never become rigidly fixed to the bone, leading to migration—and with time, loosening. Cox-2 inhibitors are widely used as postoperative analgesics, and have adverse effects on bone healing. This could tamper prosthesis fixation. We investigated whether celecoxib, a selective Cox-2 inhibitor, increases prosthesis migration in total knee replacement (TKR). Methods 50 patients were randomized to either placebo or celecoxib treatment, 200 mg twice daily, for 3 weeks after TKR (NexGen; Zimmer). Maximum total point motion (MTPM) of the tibial component was measured after 2 years using radiostereometric analysis (RSA). In addition, range of motion, pain, and, subjective outcome were evaluated. Results No differences in prosthesis migration, pain scores, range of motion, and subjective outcome were found after 2 years. Confidence intervals were narrow. Interpretation It is unlikely that Celecoxib increases the risk of loosening, and it may be used safely in conjunction with TKR.
机译:背景和目的关节置换后,修复过程从骨骼和水泥之间的界面开始。如果此过程受到干扰,则假体可能永远不会牢固地固定在骨骼上,从而导致迁移-并随着时间的流逝而松动。 Cox-2抑制剂被广泛用作术后镇痛药,并且对骨愈合有不利影响。这可能会破坏假体固定。我们研究了选择性Cox-2抑制剂celecoxib是否在全膝关节置换(TKR)中增加了假体迁移。方法将50例患者随机分为两组,分别于TKR(NexGen; Zimmer)后3周接受200 mg安慰剂或塞来昔布的治疗,每天两次。使用放射立体分析(RSA)在2年后测量胫骨组件的最大总点运动(MTPM)。此外,还评估了运动范围,疼痛和主观结果。结果2年后,假体迁移,疼痛评分,运动范围和主观结果无差异。置信区间狭窄。解释塞来昔布不太可能增加松动的风险,可以与TKR一起安全使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号